3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
NIH
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
18
Tumor-Agnostic
7
Gastrointestinal
4
Lymphoid
3
CNS
3
Plasma cell
2
Genitourinary
2
Breast
2
Other solid neoplasm
1
Gynecologic
1
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Lobular
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
423
Trastuzumab
410
Paclitaxel
375
Docetaxel
313
Capecitabine
265
Letrozole
262
Carboplatin
257
Doxorubicin
213
Tamoxifen
184
Epirubicin
176
Fulvestrant
174
Radiotherapy
171
Anastrozole
164
pembrolizumab
151
Surveys and Questionnaires
145
pertuzumab
144
Exercise
142
exemestane
128
Vinorelbine
127
palbociclib
124
Bevacizumab
123
Magnetic Resonance Spectroscopy
120
Blood Specimen Collection
120
Drug Therapy
106
Albumin-Bound Paclitaxel
105
Gemcitabine
99
130-nm albumin-bound paclitaxel
98
pyrotinib
90
eribulin
90
Biopsy
88
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Crizotinib
×
Breast
×
Clear all
NCT03620643
2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2
Completed
33 enrolled
13 charts
NCT02074878
2017-08-09
CRIZENT
Baylor Breast Care Center
Phase 1
Terminated
3 enrolled